| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AR |
| Uniprot No | O95154 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-331aa |
| 氨基酸序列 | MSRQLSRARPATVLGAMEMGRRMDAPTSAAVTRAFLERGHTEIDTAFVYSEGQSETILGGLGLRLGGSDCRVKIDTKAIPLFGNSLKPDSLRFQLETSLKRLQCPRVDLFYLHMPDHSTPVEETLRACHQLHQEGKFVELGLSNYAAWEVAEICTLCKSNGWILPTVYQGMYNAITRQVETELFPCLRHFGLRFYAFNPLAGGLLTGKYKYEDKDGKQPVGRFFGNTWAEMYRNRYWKEHHFEGIALVEKALQAAYGASAPSMTSATLRWMYHHSQLQGAHGDAVILGMSSLEQLEQNLAAAEEGPLEPAVVDAFNQAWHLVAHECPNYFR |
| 预测分子量 | 64.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于 **AR(雄激素受体)重组蛋白** 的参考文献示例，包含文献名称、作者及摘要内容概括：
---
1. **文献名称**：*"Structural basis for androgen receptor ligand binding and activation"*
**作者**：Sack, J.S. et al.
**摘要**：通过X射线晶体学解析了人雄激素受体配体结合域(LBD)与天然配体二氢睾酮(DHT)的复合物结构，揭示了AR配体结合的特异性及激活机制。
2. **文献名称**：*"Production of recombinant human androgen receptor in baculovirus-insect cell system: Functional characterization and application in drug screening"*
**作者**：Gao, W. et al.
**摘要**：利用杆状病毒-昆虫细胞系统高效表达功能性AR重组蛋白，验证其与DNA和配体的结合能力，并开发基于此的体外药物筛选平台。
3. **文献名称**：*"Androgen receptor mutations in prostate cancer: Molecular mechanisms and clinical implications"*
**作者**：Watson, P.A. et al.
**摘要**：研究AR重组蛋白中常见突变体的功能差异，揭示突变导致前列腺癌耐药性的分子机制，为靶向治疗提供依据。
4. **文献名称**：*"Development of a fluorescence polarization assay for androgen receptor-coactivator interaction inhibitors"*
**作者**：He, B. et al.
**摘要**：基于重组AR蛋白和共激活子肽段，建立荧光偏振检测方法，用于高通量筛选阻断AR信号通路的小分子抑制剂。
---
以上文献涵盖了AR重组蛋白的结构解析、表达方法、突变体功能及药物开发应用，均为该领域的代表性研究。如需具体文献来源，可进一步通过PubMed或Sci-Hub检索标题获取全文。
**Background of Recombinant AR Protein**
The androgen receptor (AR) is a steroid hormone receptor critical for mediating the effects of androgens, such as testosterone, in regulating gene expression, cellular growth, and physiological processes like sexual development and muscle maintenance. Dysregulation of AR signaling is implicated in numerous conditions, including prostate cancer, androgen insensitivity syndrome, and metabolic disorders. To study AR’s molecular mechanisms and develop targeted therapies, researchers rely on recombinant AR proteins produced via genetic engineering.
Recombinant AR proteins are generated by inserting the AR gene into expression vectors, which are then transfected into host systems (e.g., bacterial, insect, or mammalian cells). This approach enables large-scale production of purified, functional AR protein with consistent quality, overcoming limitations of isolating the receptor from native tissues. Key advantages include the ability to introduce specific mutations, tags (e.g., fluorescent or affinity tags), or truncated forms to investigate structure-function relationships, ligand binding, or interaction partners.
These engineered proteins are pivotal in drug discovery, particularly for prostate cancer, where AR signaling drives disease progression. They facilitate high-throughput screening of AR inhibitors, structural studies (e.g., X-ray crystallography) to resolve ligand-binding domains, and mechanistic analyses of resistance mutations. Additionally, recombinant AR aids in studying post-translational modifications (e.g., phosphorylation) and co-regulator recruitment that modulate AR activity.
Challenges persist in mimicking native AR behavior, such as achieving proper folding or post-translational modifications in non-mammalian systems. Advances in mammalian expression systems and cell-free protein synthesis are addressing these gaps. Overall, recombinant AR proteins remain indispensable tools for unraveling androgen signaling pathologies and accelerating therapeutic innovations.
×
